肝脏 ›› 2023, Vol. 28 ›› Issue (11): 1331-1334.

• 肝癌 • 上一篇    下一篇

IL-33通过调节NF-κB信号通路促进肝癌细胞增殖和迁移

赵盈, 田明   

  1. 727100 陕西 铜川市人民医院肛肠科(赵盈);北京中医药大学东直门医院普外科(田明)
  • 收稿日期:2023-07-16 出版日期:2023-11-30 发布日期:2024-03-03
  • 通讯作者: 田明,Email:tianming7911@126.com
  • 基金资助:
    国家自然科学基金项目(81673972)

Effect of IL-33 on the proliferation and migration of hepatocellular carcinoma cells by regulating NF-κB signaling pathway

ZHAO Ying, TIAN Ming   

  1. 1. Tongchuan People's Hospital Anorectal,Shaanxi 727100,China;
    2. Dongzhimen Hospital of Beijing University of Chinese Medicine General surgery, Beijing 100700,China
  • Received:2023-07-16 Online:2023-11-30 Published:2024-03-03
  • Contact: TIAN Ming,Email:tianming7911@126.com

摘要: 目的 探讨IL-33通过对NF-κB信号通路及炎症因子的调控,对肝癌HepG2 细胞增殖和迁移的影响。方法 RT-PCR检测IL-33在不同肝癌细胞系中的表达,Western Blot检测IL-33对HepG2 细胞NF-κB信号通路激活相关蛋白(NF-κB、p-NF-κB、IKB、p-IKB)的调控,ELISA检测IL-33对HepG2细胞中IL-1α、IL-1β、IL-6、IL-18等炎症因子释放的调控,EdU增殖实验检测IL-33对HepG2 细胞增殖的影响,CCK8实验检测IL-33对HepG2细胞24 h和48 h活力的影响,Transwell小室实验和划痕实验检测IL-33对HepG2 细胞迁移的影响。结果 IL-33 mRNA表达分别为LO2(1.01±0.01)、MHCC97H(1.08±0.05)、LM3(1.76±0.21)、HepG2(3.88±0.35)、SMCC7721(2.24±0.43)和Hep3B(2.13±0.30),差异有统计学意义(F=19.621,P=0.001)。IL-33处理24 h组中IL-1α(3185.25±194.67)、IL-1β(2103.69±124.75)、IL-6(446.58±36.82)、IL-18(1492.60±180.31),高于对照组的1001.58±18.65、1642.81±45.66、151.34±20.13、915.48±36.15,差异有统计学意义(P<0.05)。IL-33处理24 h组中NF-κB磷酸化蛋白(4.53±0.36)及IKB磷酸化蛋白(2.76±0.28)相对表达水平均高于对照组(1.25±0.23、0.49±0.09),差异有统计学意义(P<0.05)。IL-33处理24 h组细胞增殖(1.41±0.08)、24 h细胞活力(135.69±6.88)%、48 h细胞活力(176.34±25.69)%,高于对照组的(0.86±0.04)、(98.65±1.05)%、(119.89±10.86)%,差异有统计学意义(t=13.750,P<0.01;t=9.218,P<0.01;t=3.506,P=0.017)。Transwell小室和划痕实验结果发现,IL-33处理24 h组细胞侵袭数量(256.38±10.11)个、迁移相对距离(0.74±0.05),高于对照组的(185.63±23.54)个、(0.45±0.12),差异有统计学意义(t=4.783,P=0.005;t=3.864,P=0.012)。结论 IL-33可通过调控NF-κB信号通路及炎症因子等的分泌,进而促进肝癌HepG2 细胞增殖和迁移。

关键词: 肝癌, IL-33, NF-κB信号通路, 炎症, 增殖, 迁移

Abstract: Objective To investigate the effect of IL-33 on the regulation of NF-κB signaling pathway and inflammatory factors on the proliferation and migration of HepG2 cells.Methods RT-PCR was used to detect the expression of IL-33 in different hepatocellular carcinoma cell lines (LO2, MHCC97H, LM3, HepG2, SMCC7721, Hep3B). Western Blot was used to assess the regulation of IL-33 on the activation of NF-κB signaling pathway-related proteins (NF-κB, p-NF-κB, IKB, p-IKB) in HepG2 cells. ELISA was used to measure the regulation of IL-33 on the release of inflammatory factors (IL-1α, IL-1β, IL-6, IL-18) in HepG2 cells. The EdU proliferation test was conducted to detect the effect of IL-33 on the proliferation of HepG2 cells. The CCK8 test was performed to assess the viability of HepG2 cells after 24 h and 48 h of treatment with IL-33. Transwell cell test and scratch test were conducted to examine the effect of IL-33 on HepG2 cell migration.Results The RT-PCR results showed a statistically significant difference in the relative expression of IL-33mRNA between LO2 (1.01 ± 0.01), MHCC97H (1.08 ± 0.05), LM3 (1.76 ± 0.21), HepG2 (3.88 ± 0.35), SMCC7721 (2.24 ± 0.43), and Hep3B (2.13 ± 0.30) (F=19.621, P=0.001). LO2 cells and MHCC97H cells had similar expression levels, while LM3, HepG2, SMCC7721, and Hep3B showed higher expression, with HepG2 cells having the highest expression. In the 24-hour group treated with IL-33, the levels of IL-1α (3185.25 ± 194.67), IL-1β(2103.69 ± 124.75), IL-6 (446.58 ± 36.82), and IL-18 (1492.60 ± 180.31) were higher than those in the control group (1001.58 ± 18.65, 1642.81 ± 45.66, 151.34 ± 20.13, 915.48 ± 36.15), with statistical significance (P<0.05).The relative expression levels of phosphorylated NF-κB protein (4.53 ± 0.36) and phosphorylated IKB protein (2.76 ± 0.28) were higher in the 24-hour group treated with IL-33 compared to the control group (1.25 ± 0.23, 0.49 ± 0.09), with statistical significance (P<0.05). The levels of IL-1α, IL-1β, IL-6 and IL-18 factors were higher in the 24-hour group treated with IL-33 than the control group, with a statistically significant difference (P<0.05). The IL-33 treated group showed higher cell proliferation (1.41 ± 0.08), 24-hour cell viability (135.69 ± 6.88)%, and 48-hour cell viability (176.34 ± 25.69)% compared to the control group's cell proliferation (0.86 ± 0.04), and cell viability at 24 hours (98.65 ± 1.05)%, and 48 hours (119.89 ± 10.86)%, with statistically significant differences (t=13.750, P=0.000; t=9.218, P=0.000; t=3.506, P=0.017). The results of the Transwell chamber and scratch experiments indicated that the number of cell invasions (256.38 ± 10.11) and migration relative distance (0.74 ± 0.05) in the IL-33 treated group for 24 hours were higher than those in the control group (185.63 ± 23.54 and 0.45 ± 0.12, respectively), with statistically significant differences (t=4.783, P=0.005; t=3.864, P=0.012).Conclusion IL-33 can affect the inflammatory microenvironment of hepatoma cells by regulating the NF-κB signaling pathway and promote the proliferation and migration of HepG2 cells.

Key words: Hepatocellular carcinoma, IL-33, NF-κB signaling pathway, Inflammation, Proliferation, Migration